A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast
A new breast cancer drug has shown impressive results in shrinking tumours before surgery. Lapatinib (Tyverb) is licensed in the United States for advanced breast cancer but not in the European Union. It is similar to Herceptin in the
The addition of the breast cancer drug Lapatinib (Tykerb) to the Pharmaceutical Benefits Scheme (PBS) means will mean cheaper access for Australian women with an advanced stage of breast cancer.
From 20% to 30% of all breast cancer cases respond to Herceptin and these woman (try womens health) can be favorably treated with the combination in early stages. (Read the full post about Herceptin - Chemotherapy Drug Combination
A genetic fingerprint that reveals the breast cancer patients who are at high risk of the deadly spread of the disease has been found, a discovery that also reveals a new target for treatments. A pattern of gene activity that can